DialBio Secures Tens of Millions RMB in Pre-A Financing to Address Bottlenecks in Translational Research and Accelerate Innovative Drug Development

Shanghai Biaodu Bio Co., Ltd. (hereinafter referred to as “Biaodu Bio”) recently announced the completion of its Pre-A financing round, raising tens of millions of RMB. The round was led by Kentuo Capital, the industrial fund of listed company ACROBiosystems, with participation from Hongyuan Capital and additional investment from existing shareholder Hygeia Capital, which had previously provided exclusive angel funding of ten million RMB. The proceeds will be primarily used to expand and enhance the company’s existing central laboratory platform, thereby strengthening its capacity to provide innovative translational research services for biopharmaceuticals, ranging from preclinical tumor pharmacology and efficacy studies to clinical biosample analysis.

Founded in 2021, Biaodu Biology is a contract research organization (CRO) specializing in translational research services for innovative biologics. Within just over a year of its establishment, the company has built biological analysis laboratories, a qPCR P2 laboratory, and a cell biology laboratory, along with an SPF-grade small animal facility. It provides end-to-end integrated translational research services for innovative biologics, ranging from pharmacodynamics and pharmacology to clinical analytical testing. These services include central laboratory functions compliant with GLP and GCP quality management standards, preclinical and clinical biosample analysis, pharmacodynamics and pharmacology studies, and tumor immunology assays.

Dr. Ying Jiang, Co-Founder of the Company, holds a Ph.D. in Biochemistry from the University of California, Los Angeles (UCLA). She brings 15 years of drug R&D experience at internationally renowned pharmaceutical companies (Johnson & Johnson, Merck & Co.) and 13 years of management experience in drug R&D services at leading Chinese CROs. She has established multiple drug R&D translational research service platforms from the ground up and has completed or supported the regulatory submissions for dozens of Investigational New Drug (IND) or New Drug Application (NDA) projects (clinical testing and analysis programs).

Dr. Jiang Ying, CEO of Biaodu BiologyIndicates“We are deeply honored to have gained the recognition and support of a renowned investment institution in China’s biopharmaceutical sector. Adhering to the operational philosophy of people-oriented development, customer-centricity, integrity and trustworthiness, pursuit of excellence, and efficient execution, Biaodu Biotech aims to build a high-end, diversified platform for translational research technologies supporting innovative biologics. Our goal is to empower every entrepreneur to realize their vision of developing innovative biologic drugs through our platform. New drug development is a data-driven decision-making process. With an experienced and high-caliber R&D team, we provide high-quality translational research data to help clients advance innovation and translation in their drug development programs. The successful completion of this financing round reflects investors’ confidence in our team and corporate philosophy, marking a new milestone in the company’s growth. Biaodu Biotech will continue to recruit and cultivate top talent while rapidly expanding its related business operations.”

Ms. Zhao Yun, Head of Kentuo CapitalIndicates“Biaodu Bio is a clinical and preclinical translational platform and central laboratory service provider that brings together a large pool of top industry talent. I believe that as China’s innovative drug sector continues to develop, demand for platforms capable of rapidly generating high-quality clinical data will continue to rise. Biaodu will help more innovative pharmaceutical companies navigate the journey from 0 to 1. With the multifaceted support of shareholders in this funding round, we look forward to enabling Biaodu to benefit a broader range of pharmaceutical enterprises and contribute to the development of China’s pharmaceutical industry.”

Condense Capital is an industrial venture capital fund led by ACROBiosystems Group (Stock Code: 301080), focusing primarily on investing in next-generation therapeutic solutions and innovative technology platforms. Founded in 2010, ACROBiosystems is a multinational biotechnology company and a cornerstone platform enterprise that provides key biological reagent products and solutions to the global biopharmaceutical and health industries. The company was listed on the ChiNext board in 2021. With a global presence spanning Asia, North America, and Europe, ACROBiosystems Group has established subsidiaries, branches, R&D centers, and production bases in 12 cities across China, the United States, Switzerland, and other countries. To date, it has served over 6,000 clients and built long-term, stable partnerships with all of the top 20 pharmaceutical companies worldwide.

Hongyuan Investment began its equity investment business in 2005 and is one of the first 12 venture capital firms registered in Shanghai. Leveraging both proprietary and entrusted funds, the company has established a comprehensive investment strategy covering project incubation, early-stage venture capital, and mid-to-late-stage equity investments. It identifies and empowers outstanding entrepreneurs and teams, with cumulative external investments exceeding RMB 2 billion. More than ten of its portfolio companies have successfully gone public, including Menovo Pharmaceutical, Borui Medicine, and Aipeng Medical.

Hygeia Capital is a private equity investment fund focused on healthcare and biotechnology, driven by a dual strategy of “VC investment” and “investment banking services.” Its management team possesses extensive industry background and experience in equity investment. The fund’s portfolio includes numerous high-quality enterprises such as Kindly Medical Devices (1501.HK) [interventional medical devices], Cofoe Medical Technology (301087.SZ) [personal lifelong health management], Bestar [clinical CRO], Velicure Biotech [new drug R&D], ZhiDao Bio [new drug R&D], Zhongyi Anke [vaccine R&D], Respironics [inhalation formulations], Haibowei Pharma [new drug R&D], Shengsi Biopharma [new drug R&D], Kaifu Pharmaceutical [new drug R&D], Huajian Future [new drug R&D], Junyue Medicine [device CRO], Xinuo Medicine [animal experimentation center], Ruiyi Tech [pharmaceutical CDMO], Better Micro Medical [interventional/implantable medical devices], Niuchuang Medical [interventional/implantable medical devices], Hanling Medical [interventional/implantable medical devices], Biaodu Biology [preclinical CRO], Junsai Biologics [cell therapy], and Ruitai Biomedical [minimally invasive surgical medical devices], among others.